Aerts J et al. Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial. ASCO 2024;Abstract 2533.

Ahn M et al. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01. ESMO 2023;Abstract LBA12.

Eaton MS-S et al. LUNAR-2: Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150 kHz) concomitant with pembrolizumab and platinum based chemotherapy for the treatment of metastatic non-small cell lung cancer. ASCO 2024;Abstract TPS8665.

Garassino MC et al. Sacituzumab govitecan vs docetaxel in patients with mNSCLC non-responsive to last anti-PD-(L)1-containing regimen: EVOKE-01. WCLC 2024;Abstract OA08.06.

Garassino MC et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol 2023;41(11):1992-8. Abstract

Gray J et al. Sacituzumab govitecan + pembrolizumab + carboplatin in 1L metastatic non-small cell lung cancer: The EVOKE-02 study. WCLC 2024;Abstract OA08.07.

Kilickap S et al. Cemiplimab monotherapy for first line advanced NSCLC patients with PD-L1 expression ≥50%: 5-y outcomes of EMPOWER-Lung 1. WCLC 2024;Abstract OA11.06.

Leal T et al. Tumor treating field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study. ASCO 2023;Abstract LBA9005.

Leal T et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): A randomised, open-label, pivotal phase 3 study. Lancet Oncol 2023;24(9):1002-17. Abstract

Levy BP et al. Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02. ASCO 2024;Abstract 8617.

Makharadze T et al. Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-Lung 3 part 2 trial. J Thorac Oncol 2023;18(6):755-68. Abstract

Peters S et al. Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line metastatic (m) NSCLC: 5-year overall survival (OS) update from the POSEIDON study. ESMO Immuno-Oncology Congress 2023;Abstract LBA3.

Ramalingam SS et al. Six-year survival and HRQoL outcomes with 1L nivolumab + ipilimumab in patients with metastatic NSCLC from CheckMate227. WCLC 2023;Abstract OA14.03.

Reck M et al. Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA. ASCO 2024;Abstract 8560.

Sands J et al. Datopotamab deruxtecan vs docetaxel in patients with non-small cell lung cancer: Final overall survival from TROPION-Lung01. WCLC 2024;Abstract OA08.03.

Zhou C et al. Phase 3 study of ivonescimab (AK112) vs. pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC: Primary analysis of HARMONi-2. WCLC 2024;Abstract PL02.04.